[
    "Fig. 1 Bioactive molecules with chiral THQs and DHQs.",
    "Scheme 1 Asymmetric synthesis of chiral THQs and DHQs.",
    "Scheme 2 Asymmetric homogeneous hydrogenation of substrate3junder continuous flow conditions.",
    "Fig. 2 1H NMR study of the interaction ofL1(0.02 M) with1f(0.06 M) and3a(0.06 M) in CDCl3.",
    "Scheme 3 Deuterium labeling experiment and the proposed transformation path.",
    "Scheme 4 Outer-sphere mechanism for quinoxaline asymmetric hydrogenation.",
    "Fig. 3 DFT calculated energy potential surface for the proposed pathway (Ar = 3,5-di-CF3Ph; the phenyl groups on the phosphorus atoms are omitted for clarity; the relative Gibbs energies are labeled in kcal molâˆ’1).",
    "Table 1 Optimization of the reaction conditions for asymmetric hydrogenation of 2-methylquinoxaline hydrochloride1aa [a] Reaction conditions:1a(0.25 mmol) in 2 mL solvent,1a/[Rh(cod)Cl]2/ligand ratio = 100/0.5/1. [b] Catalytic precursor is [Ir(cod)Cl]2. [c] The reaction time is 12 h. [d] S/C = 1000. [e] S/C = 1500. [f] Without HCl. Conversion was determined by1H NMR analysis. ee was determined by HPLC.",
    "Table 2 Ligand evaluation for asymmetric hydrogenation of 2-methylquinoxaline hydrochloride1aa [a] Reaction conditions:1a(0.25 mmol) in 2 mL solvent,1a/[Rh(cod)Cl]2/ligand ratio = 100/0.5/1; conversion was determined by1H NMR analysis; ee was determined by HPLC.",
    "Table 3 Scope of quinoxaline derivativesa [a] Reaction conditions:1a(0.25 mmol) in 4 mL dry DCM,1a/[Rh(cod)Cl]2/L1ratio = 100/0.5/1; yield was determined with isolated products; ee was determined by HPLC. [b] 1i(1.08 g, 5 mmol) in 10 mL dry DCM, H2(2 MPa), 24 h.",
    "Table 4 Scope of quinoxalinone derivativesa [a] Reaction conditions:3(0.25 mmol) in 4 mL dry DCM,3/[Rh(cod)Cl]2/L1ratio = 100/0.5/1; yield was determined with isolated products; ee was determined by HPLC. [b] 3a(1.05 g, 5 mmol) in 10 mL dry DCM, H2(2 MPa), 24 h."
]